Health ❯ Healthcare ❯ Patient Care ❯ Treatment Options

Combination Therapy

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

The ruling follows phase 3 data showing longer survival with relacorilant plus nab-paclitaxel.

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer